Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Colorectal Neoplasms

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 48 articles: HTML format Text format

Single Articles

March 2019
1. PUCCINI A, Loupakis F, Stintzing S, Cao S, et al
   Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.
   Eur J Cancer. 2019;111:138-147.
   PubMed     Text format     Abstract available
   
   
   February 2019
2. KOSUMI K, Hamada T, Zhang S, Liu L, et al
   Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
   Eur J Cancer. 2019;111:82-93.
   PubMed     Text format     Abstract available
   
   
   
3. CASCINU S, Poli D, Zaniboni A, Lonardi S, et al
   The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
   Eur J Cancer. 2019;111:1-7.
   PubMed     Text format     Abstract available
   
   
   
4. CREMOLINI C, Marmorino F, Bergamo F, Aprile G, et al
   Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
   Eur J Cancer. 2019;109:175-182.
   PubMed     Text format     Abstract available
   
   
   January 2019
5. MODEST DP, Pant S, Sartore-Bianchi A
   Treatment sequencing in metastatic colorectal cancer.
   Eur J Cancer. 2019;109:70-83.
   PubMed     Text format     Abstract available
   
   
   December 2018
6. SCHWARTZ S, Szeto C, Tian Y, Cecchi F, et al
   Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
   Eur J Cancer. 2018;107:164-174.
   PubMed     Text format     Abstract available
   
   
   
7. SUENAGA M, Stintzing S, Cao S, Zhang W, et al
   Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
   Eur J Cancer. 2018;107:100-114.
   PubMed     Text format     Abstract available
   
   
   November 2018
8. HOLCH JW, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
   Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
   Eur J Cancer. 2018;106:115-125.
   PubMed     Text format     Abstract available
   
   
   
9. BARANISKIN A, Buchberger B, Pox C, Graeven U, et al
   Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
   Eur J Cancer. 2018;106:37-44.
   PubMed     Text format     Abstract available
   
   
   
10. IMANISHI M, Yamamoto Y, Hamano Y, Yamada T, et al
    Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.
    Eur J Cancer. 2018;106:69-77.
    PubMed     Text format     Abstract available
    
    
    October 2018
11. MOLOGNI L
    Synergistic activity of dasatinib in combination with beta-catenin blockade in colorectal cancer cells.
    Eur J Cancer. 2018 Oct 12. pii: S0959-8049(18)31366.
    PubMed     Text format    
    
    
    September 2018
12. SALEM ME, Yin J, Weinberg BA, Renfro LA, et al
    Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD dat
    Eur J Cancer. 2018;103:205-213.
    PubMed     Text format     Abstract available
    
    
    
13. LORD AC, D'Souza N, Pucher PH, Moran BJ, et al
    Author response to comment on 'significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis'.
    Eur J Cancer. 2018 Sep 25. pii: S0959-8049(18)31336.
    PubMed     Text format    
    
    
    
14. GOOTJES EC, Bakkerus L, Ten Tije AJ, Witteveen PO, et al
    The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer.
    Eur J Cancer. 2018;103:160-164.
    PubMed     Text format     Abstract available
    
    
    
15. HAMADA T, Liu L, Nowak JA, Mima K, et al
    Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour.
    Eur J Cancer. 2018;103:98-107.
    PubMed     Text format     Abstract available
    
    
    
16. HIRST Y, Stoffel S, Baio G, McGregor L, et al
    Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out.
    Eur J Cancer. 2018 Sep 6. pii: S0959-8049(18)31120.
    PubMed     Text format     Abstract available
    
    
    August 2018
17. MADI A, Fisher D, Maughan TS, Colley JP, et al
    Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Eur J Cancer. 2018;102:31-39.
    PubMed     Text format     Abstract available
    
    
    
18. TEJPAR S, Yan P, Piessevaux H, Dietrich D, et al
    Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Eur J Cancer. 2018;99:66-77.
    PubMed     Text format     Abstract available
    
    
    July 2018
19. ARANDA E, Garcia Alfonso P, Benavides M, Sanchez Ruiz A, et al
    First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    Eur J Cancer. 2018 Jul 24. pii: S0959-8049(18)30938.
    PubMed     Text format     Abstract available
    
    
    
20. HEGEWISCH-BECKER S, Nopel-Dunnebacke S, Hinke A, Graeven U, et al
    Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
    Eur J Cancer. 2018;101:105-113.
    PubMed     Text format     Abstract available
    
    
    
21. GELLI M, Huguenin JFL, de Baere T, Benhaim L, et al
    Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
    Eur J Cancer. 2018;100:94-103.
    PubMed     Text format     Abstract available
    
    
    June 2018
22. GOEY KKH, Sorbye H, Glimelius B, Adams RA, et al
    Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
    Eur J Cancer. 2018;100:35-45.
    PubMed     Text format     Abstract available
    
    
    
23. STOCKER G, Hacker UT, Fiteni F, John Mahachie J, et al
    Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
    Eur J Cancer. 2018;99:49-57.
    PubMed     Text format     Abstract available
    
    
    May 2018
24. APARICIO T, Ducreux M, Faroux R, Barbier E, et al
    Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
    Eur J Cancer. 2018;98:1-9.
    PubMed     Text format     Abstract available
    
    
    
25. APARICIO T, Bouche O, Francois E, Retornaz F, et al
    Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
    Eur J Cancer. 2018;97:16-24.
    PubMed     Text format     Abstract available
    
    
    
26. AUCLIN E, Andre T, Taieb J, Benetkiewicz M, et al
    Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.
    Eur J Cancer. 2018 May 3. pii: S0959-8049(18)30782.
    PubMed     Text format    
    
    
    
27. GOEY KKH, Mahmoud R, Sorbye H, Glimelius B, et al
    Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.
    Eur J Cancer. 2018;96:115-124.
    PubMed     Text format     Abstract available
    
    
    April 2018
28. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Eur J Cancer. 2018;96:105-110.
    PubMed     Text format     Abstract available
    
    
    
29. MATSUDA C, Ishiguro M, Teramukai S, Kajiwara Y, et al
    A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Eur J Cancer. 2018;96:54-63.
    PubMed     Text format     Abstract available
    
    
    March 2018
30. TACHON G, Frouin E, Karayan-Tapon L, Auriault ML, et al
    Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.
    Eur J Cancer. 2018 Mar 5. pii: S0959-8049(18)30121.
    PubMed     Text format    
    
    
    
31. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.
    Eur J Cancer. 2018;94:1-5.
    PubMed     Text format     Abstract available
    
    
    
32. OGURA A, Akiyoshi T, Yamamoto N, Kawachi H, et al
    Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
    Eur J Cancer. 2018;91:11-20.
    PubMed     Text format     Abstract available
    
    
    February 2018
33. YOSHINO T, Hsu Y, Nasroulah F
    Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
    Eur J Cancer. 2018 Feb 9. pii: S0959-8049(18)30084.
    PubMed     Text format    
    
    
    
34. ZOU D, Lou J, Ke J, Mei S, et al
    Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression.
    Eur J Cancer. 2018;93:1-9.
    PubMed     Text format     Abstract available
    
    
    January 2018
35. VAN ROOIJEN KL, Shi Q, Goey KKH, Meyers J, et al
    Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
    Eur J Cancer. 2018;91:99-106.
    PubMed     Text format     Abstract available
    
    
    
36. IBRAHIM S, Raoul W, Lecomte T, Paintaud G, et al
    Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31461.
    PubMed     Text format    
    
    
    
37. VON MOOS R, Koeberle D, Schacher S, Hayoz S, et al
    Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
    Eur J Cancer. 2018;89:82-89.
    PubMed     Text format     Abstract available
    
    
    
38. SWETS M, Kuppen PJK, Blok EJ, Gelderblom H, et al
    Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?
    Eur J Cancer. 2018;89:1-8.
    PubMed     Text format     Abstract available
    
    
    December 2017
39. VAN CUTSEM E, Mayer RJ, Laurent S, Winkler R, et al
    The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Eur J Cancer. 2017;90:63-72.
    PubMed     Text format     Abstract available
    
    
    November 2017
40. MODEST DP, Denecke T, Pratschke J, Ricard I, et al
    Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    Eur J Cancer. 2017;88:77-86.
    PubMed     Text format     Abstract available
    
    
    
41. COHEN R, Buhard O, Cervera P, Hain E, et al
    Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Eur J Cancer. 2017;86:266-274.
    PubMed     Text format     Abstract available
    
    
    October 2017
42. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
    Eur J Cancer. 2017;86:197-206.
    PubMed     Text format     Abstract available
    
    
    
43. KEIKES L, Koopman M, Tanis PJ, Lemmens VEPP, et al
    Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.
    Eur J Cancer. 2017;86:166-177.
    PubMed     Text format     Abstract available
    
    
    
44. PREVOSTEL C, Blache P
    The dose-dependent effect of SOX9 and its incidence in colorectal cancer.
    Eur J Cancer. 2017;86:150-157.
    PubMed     Text format     Abstract available
    
    
    
45. MALKA D, Rotolo F, Boige V
    First-line treatment in metastatic colorectal cancer: Important or crucial?
    Eur J Cancer. 2017;84:363-366.
    PubMed     Text format    
    
    
    September 2017
46. TURATI F, Bravi F, Di Maso M, Bosetti C, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and colorectal cancer risk.
    Eur J Cancer. 2017;85:86-94.
    PubMed     Text format     Abstract available
    
    
    August 2017
47. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    PubMed     Text format    
    
    
    January 2017
48. CHAN AK, Siriwardena AK
    Management of synchronous liver metastases and the recommendations of the second St. Gallen European Organisation for Research and Treatment of Cancer consensus conference on the management of rectal cancer.
    Eur J Cancer. 2017;71:51-52.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: